PMID- 24888777
OWN - NLM
STAT- MEDLINE
DCOM- 20150209
LR  - 20151119
IS  - 1440-1827 (Electronic)
IS  - 1320-5463 (Linking)
VI  - 64
IP  - 5
DP  - 2014 May
TI  - Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex 
      ligation-dependent probe amplification and fluorescence in situ hybridization.
PG  - 231-6
LID - 10.1111/pin.12158 [doi]
AB  - A needle biopsy of a mass in the right breast of a 36-year-old woman revealed 
      invasive ductal carcinoma (IDC), and approximately 20% of cancer cells showed 
      unequivocal membranous staining with the HercepTest. After systemic therapy with 
      trastuzumab and paclitaxel followed by FEC (fluorouracil + epirubicin + 
      cyclophosphamide), a right mastectomy was performed. By histological and 
      immunohistochemical examinations, the resected tumor consisted mainly of 
      E-cadherin-negative invasive lobular carcinoma (ILC), and the rest was 
      ERBB2-positive IDC; thus, the diagnosis was mixed ductal and lobular carcinoma. 
      Multiplex ligation-dependent probe amplification and fluorescence in situ 
      hybridization (FISH) analyses revealed that ILC and IDC shared high-level 
      amplification of CCND1 in homogeneously staining regions (HSR) and that IDC had 
      an additional HSR-type amplicon of ERBB2. These findings strongly indicate that 
      IDC and ILC had a common precursor cell with CCND1 amplification. Review of the 
      biopsy specimen with FISH showed IDC with gene amplifications of CCND1 and ERBB2 
      as a minor component, IDC without amplification of CCND1 or ERBB2 as a major 
      component, and a minute portion of ILC with CCND1 amplification. We speculate 
      that chemotherapy and trastuzumab caused a marked reduction in IDC; however, ILC 
      with CCND1 amplification was resistant to chemotherapy and grew.
CI  - (c) 2014 The Authors. Pathology International (c) 2014 Japanese Society of Pathology 
      and Wiley Publishing Asia Pty Ltd.
FAU - Tajiri, Ryosuke
AU  - Tajiri R
AD  - Department of Molecular and Cellular Pathology, Kanazawa University, Ishikawa.
FAU - Inokuchi, Masafumi
AU  - Inokuchi M
FAU - Sawada-Kitamura, Seiko
AU  - Sawada-Kitamura S
FAU - Kawashima, Hiroko
AU  - Kawashima H
FAU - Nakamura, Ritsuko
AU  - Nakamura R
FAU - Oyama, Takeru
AU  - Oyama T
FAU - Dobashi, Yoh
AU  - Dobashi Y
FAU - Ooi, Akishi
AU  - Ooi A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Pathol Int
JT  - Pathology international
JID - 9431380
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCND1 protein, human)
RN  - 0 (DNA, Neoplasm)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Biopsy, Needle
MH  - Breast/metabolism/pathology
MH  - Breast Neoplasms/*genetics/metabolism/therapy
MH  - Carcinoma, Ductal, Breast/*genetics/metabolism/therapy
MH  - Carcinoma, Lobular/*genetics/metabolism/therapy
MH  - Cyclin D1/genetics/metabolism
MH  - DNA Fingerprinting/*methods
MH  - DNA, Neoplasm/*genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Mastectomy
MH  - Multiplex Polymerase Chain Reaction/*methods
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - FISH
OT  - MLPA
OT  - breast cancer
OT  - ductal carcinoma
OT  - lobular carcinoma
EDAT- 2014/06/04 06:00
MHDA- 2015/02/11 06:00
CRDT- 2014/06/04 06:00
PHST- 2014/02/01 00:00 [received]
PHST- 2014/03/25 00:00 [accepted]
PHST- 2014/06/04 06:00 [entrez]
PHST- 2014/06/04 06:00 [pubmed]
PHST- 2015/02/11 06:00 [medline]
AID - 10.1111/pin.12158 [doi]
PST - ppublish
SO  - Pathol Int. 2014 May;64(5):231-6. doi: 10.1111/pin.12158.